Taming a mutinous mutant: an errant receptor becomes a prime cancer target. Journal of the National Cancer Institute [J Natl Cancer Inst] Journal article

Title	Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
Author(s)	Goldman B
Source	J Natl Cancer Inst 2007 Apr 4; 99(7):504-5.
MeSH	Antineoplastic Agents, Alkylating Brain Neoplasms Cancer Vaccines Combined Modality Therapy Dacarbazine Glioblastoma Humans Mutation
Language	eng
Pub Type(s)	News
PubMed ID	17405993

Advertise on this site.